Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIobenguane
Identification
- Name
- Iobenguane
- Accession Number
- DB06704 (DB09497)
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Description
Synthetic guanethidine derivative that locates phaeochromocytomas and neuroblastomas. The radioisotope used can either be iodine-123 for imaging or iodine-131 for destruction of tissues that metabolize noradrenaline. Iodine 123 is a cyclotron-produced radionuclide that decays to Te 123 by electron capture. Images are produced by a I123 MIBG scintigraphy. FDA approved on September 19, 2008.
- Structure
Structure for DB06704 (Iobenguane)
- Synonyms
- ((3-iodophenyl)methyl)guanidine
- 3-iodobenzylguanidine
- m-iodobenzylguanidine
- Metaiodobenzylguanidine
- mIBG
- Product Ingredients
Ingredient UNII CAS InChI Key Iobenguane I 123 P2TH1XYZ84 76924-93-1 PDWUPXJEEYOOTR-IUAIQHPESA-N Iobenguane I 131 Q461L7AK4R 77679-27-7 PDWUPXJEEYOOTR-JRGAVVOBSA-N Iobenguane sulfate S8I0922465 87862-25-7 XNACDNPGABUBFR-UHFFFAOYSA-N Iobenguane sulfate I 123 Not Available 139755-80-9 Not applicable Iobenguane sulfate I 131 M575VKV19N 149210-33-3 Not applicable - Categories
- UNII
- 35MRW7B4AD
- CAS number
- 80663-95-2
- Weight
- Average: 275.0896
Monoisotopic: 274.991940755 - Chemical Formula
- C8H10IN3
- InChI Key
- PDWUPXJEEYOOTR-UHFFFAOYSA-N
- InChI
- InChI=1S/C8H10IN3/c9-7-3-1-2-6(4-7)5-12-8(10)11/h1-4H,5H2,(H4,10,11,12)
- IUPAC Name
- 2-[(3-iodophenyl)methyl]guanidine
- SMILES
- NC(N)=NCC1=CC(I)=CC=C1
Pharmacology
- Indication
Detection of primary and metastatic pheochromocytoma or neuroblastoma
- Structured Indications
- Not Available
- Pharmacodynamics
AdreView is a diagnostic radiopharmaceutical which contains a small quantity of iobenguane that is not expected to produce a pharmacodynamic effect. Patients with renal insufficiency may experience increased radiation exposure and impaired imaging results.
- Mechanism of action
Structure of iobenguane is similar to noradrenaline so it can be taken up by adrenergic tissue in the adrenal medulla, liver, heart, and spleen. Once taken up by noradrenaline transporters in the adrenergic nerve terminals, it is stored in the presynaptic storage vesicles. The radioactive iodine component is responsible for its imaging properties.
- Absorption
Iobenguane rapidly clears from the blood and is highly retained in adrenergic tissues.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
Less than 10% of the dose is metabolized into m-iodohippuric acid (MIHA). However the mechanism in which this metabolite is produced is unknown.
- Route of elimination
Renally excreted unchanged (70%-90%) via glomerular filtration; Fecal (<1%)
- Half life
Physical half life = 13.2 hours
- Clearance
- Not Available
- Toxicity
Oral mouse: LD50 = 300 mg/kg; Oral, rabbit: LD50 = 3200 mg/kg; Oral, rat: LD50=980 mg/kg. The most common adverse reactions, dizziness, rash, pruritis, flushing, headache, and injection site hemorrhage occurred in < 1.3% of patients.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 4-Methoxyamphetamine The therapeutic efficacy of Iobenguane can be decreased when used in combination with 4-Methoxyamphetamine. Experimental, Illicit Acebutolol The therapeutic efficacy of Iobenguane can be decreased when used in combination with Acebutolol. Approved, Investigational Acetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Iobenguane. Approved Acetyldigoxin Acetyldigoxin may decrease the cardiotoxic activities of Iobenguane. Experimental Agmatine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Agmatine. Experimental, Investigational Alaproclate The therapeutic efficacy of Iobenguane can be decreased when used in combination with Alaproclate. Experimental Amineptine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Amineptine. Illicit, Withdrawn Amitriptyline The therapeutic efficacy of Iobenguane can be decreased when used in combination with Amitriptyline. Approved Amoxapine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Amoxapine. Approved Amphetamine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Amphetamine. Approved, Illicit, Investigational Ancestim The risk or severity of cytotoxicity can be increased when Ancestim is combined with Iobenguane. Approved, Investigational, Withdrawn Apomorphine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Apomorphine. Approved, Investigational Benzphetamine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Benzphetamine. Approved, Illicit Bethanidine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Bethanidine. Approved Bevacizumab Bevacizumab may increase the cardiotoxic activities of Iobenguane. Approved, Investigational Brimonidine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Brimonidine. Approved Bromocriptine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Bromocriptine. Approved, Investigational Bucindolol The therapeutic efficacy of Iobenguane can be decreased when used in combination with Bucindolol. Investigational Cabazitaxel The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Iobenguane. Approved Celiprolol The therapeutic efficacy of Iobenguane can be decreased when used in combination with Celiprolol. Approved, Investigational Chlorphentermine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Chlorphentermine. Illicit, Withdrawn Citalopram The therapeutic efficacy of Iobenguane can be decreased when used in combination with Citalopram. Approved Clenbuterol The therapeutic efficacy of Iobenguane can be decreased when used in combination with Clenbuterol. Approved, Investigational, Vet Approved Clomipramine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Clomipramine. Approved, Investigational, Vet Approved Clonidine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Clonidine. Approved Cocaine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Cocaine. Approved, Illicit Cyclobenzaprine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Cyclobenzaprine. Approved Cyclophosphamide Cyclophosphamide may increase the cardiotoxic activities of Iobenguane. Approved, Investigational Cymarin Cymarin may decrease the cardiotoxic activities of Iobenguane. Experimental Dapoxetine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Dapoxetine. Investigational Desipramine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Desipramine. Approved, Investigational Deslanoside Deslanoside may decrease the cardiotoxic activities of Iobenguane. Approved Desvenlafaxine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Desvenlafaxine. Approved, Investigational Dexmedetomidine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Dexmedetomidine. Approved, Vet Approved Dibenzepin The therapeutic efficacy of Iobenguane can be decreased when used in combination with Dibenzepin. Experimental Digitoxin Digitoxin may decrease the cardiotoxic activities of Iobenguane. Approved, Investigational Digoxin Digoxin may decrease the cardiotoxic activities of Iobenguane. Approved Digoxin Immune Fab (Ovine) Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Iobenguane. Approved Dihydroergotamine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Dihydroergotamine. Approved, Investigational Dipivefrin The therapeutic efficacy of Iobenguane can be decreased when used in combination with Dipivefrin. Approved Dobutamine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Dobutamine. Approved Docetaxel The risk or severity of adverse effects can be increased when Docetaxel is combined with Iobenguane. Approved, Investigational Dopamine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Dopamine. Approved Dosulepin The therapeutic efficacy of Iobenguane can be decreased when used in combination with Dosulepin. Approved Doxepin The therapeutic efficacy of Iobenguane can be decreased when used in combination with Doxepin. Approved, Investigational Droxidopa The therapeutic efficacy of Iobenguane can be decreased when used in combination with Droxidopa. Approved, Investigational Duloxetine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Duloxetine. Approved Epanolol The therapeutic efficacy of Iobenguane can be decreased when used in combination with Epanolol. Experimental Ephedra The therapeutic efficacy of Iobenguane can be decreased when used in combination with Ephedra. Approved, Nutraceutical, Withdrawn Ephedrine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Ephedrine. Approved Epinephrine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Epinephrine. Approved, Vet Approved Ergotamine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Ergotamine. Approved Escitalopram The therapeutic efficacy of Iobenguane can be decreased when used in combination with Escitalopram. Approved, Investigational Esmirtazapine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Esmirtazapine. Investigational Etilefrine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Etilefrine. Withdrawn Etomidate The therapeutic efficacy of Iobenguane can be decreased when used in combination with Etomidate. Approved Etoperidone The therapeutic efficacy of Iobenguane can be decreased when used in combination with Etoperidone. Withdrawn Fenoterol The therapeutic efficacy of Iobenguane can be decreased when used in combination with Fenoterol. Approved, Investigational Fenozolone The therapeutic efficacy of Iobenguane can be decreased when used in combination with Fenozolone. Experimental Fluoxetine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Fluoxetine. Approved, Vet Approved Fluvoxamine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Fluvoxamine. Approved, Investigational Gitoformate Gitoformate may decrease the cardiotoxic activities of Iobenguane. Experimental Guanabenz The therapeutic efficacy of Iobenguane can be decreased when used in combination with Guanabenz. Approved, Investigational Guanfacine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Guanfacine. Approved, Investigational Hydroxyamphetamine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Hydroxyamphetamine. Approved Imipramine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Imipramine. Approved Indalpine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Indalpine. Investigational, Withdrawn Iprindole The therapeutic efficacy of Iobenguane can be decreased when used in combination with Iprindole. Experimental Isoprenaline The therapeutic efficacy of Iobenguane can be decreased when used in combination with Isoprenaline. Approved, Investigational Isoxsuprine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Isoxsuprine. Approved, Withdrawn Labetalol The therapeutic efficacy of Iobenguane can be decreased when used in combination with Labetalol. Approved Lanatoside C Lanatoside C may decrease the cardiotoxic activities of Iobenguane. Experimental Levomilnacipran The therapeutic efficacy of Iobenguane can be decreased when used in combination with Levomilnacipran. Approved, Investigational Levonordefrin The therapeutic efficacy of Iobenguane can be decreased when used in combination with Levonordefrin. Approved Lofepramine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Lofepramine. Experimental Lofexidine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Lofexidine. Approved, Investigational Mefenorex The therapeutic efficacy of Iobenguane can be decreased when used in combination with Mefenorex. Experimental Mephentermine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Mephentermine. Approved Metaraminol The therapeutic efficacy of Iobenguane can be decreased when used in combination with Metaraminol. Approved, Investigational Methamphetamine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Methamphetamine. Approved, Illicit Methoxamine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Methoxamine. Approved, Investigational Methyldopa The therapeutic efficacy of Iobenguane can be decreased when used in combination with Methyldopa. Approved Metildigoxin Metildigoxin may decrease the cardiotoxic activities of Iobenguane. Experimental Midodrine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Midodrine. Approved Milnacipran The therapeutic efficacy of Iobenguane can be decreased when used in combination with Milnacipran. Approved, Investigational Mirtazapine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Mirtazapine. Approved Moxonidine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Moxonidine. Approved, Investigational Naphazoline The therapeutic efficacy of Iobenguane can be decreased when used in combination with Naphazoline. Approved Nefazodone The therapeutic efficacy of Iobenguane can be decreased when used in combination with Nefazodone. Approved, Withdrawn Norepinephrine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Norepinephrine. Approved Nortriptyline The therapeutic efficacy of Iobenguane can be decreased when used in combination with Nortriptyline. Approved Nylidrin The therapeutic efficacy of Iobenguane can be decreased when used in combination with Nylidrin. Approved Oleandrin Oleandrin may decrease the cardiotoxic activities of Iobenguane. Experimental, Investigational Opipramol The therapeutic efficacy of Iobenguane can be decreased when used in combination with Opipramol. Investigational Orciprenaline The therapeutic efficacy of Iobenguane can be decreased when used in combination with Orciprenaline. Approved Ouabain Ouabain may decrease the cardiotoxic activities of Iobenguane. Approved Oxymetazoline The therapeutic efficacy of Iobenguane can be decreased when used in combination with Oxymetazoline. Approved, Investigational Paclitaxel The risk or severity of adverse effects can be increased when Paclitaxel is combined with Iobenguane. Approved, Vet Approved Paliperidone The therapeutic efficacy of Iobenguane can be decreased when used in combination with Paliperidone. Approved Paroxetine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Paroxetine. Approved, Investigational Pergolide The therapeutic efficacy of Iobenguane can be decreased when used in combination with Pergolide. Approved, Investigational, Vet Approved, Withdrawn Peruvoside Peruvoside may decrease the cardiotoxic activities of Iobenguane. Experimental Phenmetrazine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Phenmetrazine. Approved, Illicit Phentermine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Phentermine. Approved, Illicit Phenylephrine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Phenylephrine. Approved Phenylpropanolamine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Phenylpropanolamine. Approved, Vet Approved, Withdrawn Prenalterol The therapeutic efficacy of Iobenguane can be decreased when used in combination with Prenalterol. Experimental Procaterol The therapeutic efficacy of Iobenguane can be decreased when used in combination with Procaterol. Approved, Investigational Proscillaridin Proscillaridin may decrease the cardiotoxic activities of Iobenguane. Experimental Protriptyline The therapeutic efficacy of Iobenguane can be decreased when used in combination with Protriptyline. Approved Pseudoephedrine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Pseudoephedrine. Approved Racepinephrine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Racepinephrine. Approved Reserpine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Reserpine. Approved, Investigational Risperidone The therapeutic efficacy of Iobenguane can be decreased when used in combination with Risperidone. Approved, Investigational Ritodrine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Ritodrine. Approved, Investigational Ropinirole The therapeutic efficacy of Iobenguane can be decreased when used in combination with Ropinirole. Approved, Investigational Sertraline The therapeutic efficacy of Iobenguane can be decreased when used in combination with Sertraline. Approved Synephrine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Synephrine. Experimental Terbutaline The therapeutic efficacy of Iobenguane can be decreased when used in combination with Terbutaline. Approved Tetryzoline The therapeutic efficacy of Iobenguane can be decreased when used in combination with Tetryzoline. Approved Tianeptine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Tianeptine. Approved, Investigational Tizanidine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Tizanidine. Approved, Investigational Tramazoline The therapeutic efficacy of Iobenguane can be decreased when used in combination with Tramazoline. Investigational Trastuzumab Trastuzumab may increase the cardiotoxic activities of Iobenguane. Approved, Investigational Tretoquinol The therapeutic efficacy of Iobenguane can be decreased when used in combination with Tretoquinol. Experimental Trimipramine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Trimipramine. Approved Tyramine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Tyramine. Investigational, Nutraceutical Venlafaxine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Venlafaxine. Approved Xylometazoline The therapeutic efficacy of Iobenguane can be decreased when used in combination with Xylometazoline. Approved, Investigational Zimelidine The therapeutic efficacy of Iobenguane can be decreased when used in combination with Zimelidine. Withdrawn - Food Interactions
- Not Available
References
- General References
- Wafelman AR, Hoefnagel CA, Maes RA, Beijnen JH: Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med. 1994 Jun;21(6):545-59. [PubMed:8082671]
- External Links
- KEGG Drug
- D04559
- PubChem Compound
- 60860
- PubChem Substance
- 175427085
- ChemSpider
- 54847
- ChEBI
- 92769
- ChEMBL
- CHEMBL818
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Iobenguane
- ATC Codes
- V09IX02 — Iobenguane (131i)
- V09IX — Other diagnostic radiopharmaceuticals for tumour detection
- V09I — TUMOUR DETECTION
- V09 — DIAGNOSTIC RADIOPHARMACEUTICALS
- V — VARIOUS
- V09IX — Other diagnostic radiopharmaceuticals for tumour detection
- V09I — TUMOUR DETECTION
- V09 — DIAGNOSTIC RADIOPHARMACEUTICALS
- V — VARIOUS
- FDA label
- Download (187 KB)
- MSDS
- Download (93.8 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Terminated Treatment Congestive Heart Failure (CHF) 1 1, 2 Completed Treatment Paraganglioma / Pheochromocytomas 1 1, 2 Unknown Status Treatment Neuroblastomas 1 2 Recruiting Treatment MIBG Avid Tumors 1 3 Completed Diagnostic Congestive Heart Failure (CHF) 2 3 Completed Treatment Neoplasm Metastases / Neuroendocrine Tumors 1 4 Completed Diagnostic Heart Failure, Unspecified / Ventricular Dysfunction, Left 1 Not Available Approved for Marketing Not Available Neuroblastomas 1 Not Available Available Not Available Childhood Metastatic Pheochromocytoma / Neuroblastomas / Paraganglioma 1 Not Available Available Not Available Neuroblastomas 1 Not Available Available Not Available Neuroblastomas / Pheochromocytomas 1 Not Available Available Not Available Paraganglioma / Pheochromocytomas 1 Not Available Completed Treatment Neuroblastomas 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Liquid
- Experimental Properties
Property Value Source melting point (°C) 0°C MSDS boiling point (°C) 100°C MSDS water solubility Soluble MSDS - Predicted Properties
Property Value Source Water Solubility 0.0878 mg/mL ALOGPS logP 1.53 ALOGPS logP 1.64 ChemAxon logS -3.5 ALOGPS pKa (Strongest Basic) 11.27 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 64.4 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 58.32 m3·mol-1 ChemAxon Polarizability 21.93 Å3 ChemAxon Number of Rings 1 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9057 Blood Brain Barrier + 0.9003 Caco-2 permeable + 0.5774 P-glycoprotein substrate Non-substrate 0.6467 P-glycoprotein inhibitor I Non-inhibitor 0.9591 P-glycoprotein inhibitor II Non-inhibitor 0.8833 Renal organic cation transporter Inhibitor 0.5244 CYP450 2C9 substrate Non-substrate 0.8712 CYP450 2D6 substrate Non-substrate 0.6132 CYP450 3A4 substrate Non-substrate 0.7951 CYP450 1A2 substrate Inhibitor 0.9029 CYP450 2C9 inhibitor Non-inhibitor 0.9071 CYP450 2D6 inhibitor Inhibitor 0.8932 CYP450 2C19 inhibitor Non-inhibitor 0.9026 CYP450 3A4 inhibitor Non-inhibitor 0.9069 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9122 Ames test Non AMES toxic 0.7308 Carcinogenicity Non-carcinogens 0.9184 Biodegradation Not ready biodegradable 0.9961 Rat acute toxicity 2.9081 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9369 hERG inhibition (predictor II) Non-inhibitor 0.9283
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as iodobenzenes. These are aromatic compounds containing one or more iodine atoms attached to a benzene.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Halobenzenes
- Direct Parent
- Iodobenzenes
- Alternative Parents
- Aryl iodides / Guanidines / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Organopnictogen compounds / Organoiodides / Hydrocarbon derivatives
- Substituents
- Iodobenzene / Aryl iodide / Aryl halide / Guanidine / Organic 1,3-dipolar compound / Propargyl-type 1,3-dipolar organic compound / Carboximidamide / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Substrate
- General Function
- Norepinephrine:sodium symporter activity
- Specific Function
- Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
- Gene Name
- SLC6A2
- Uniprot ID
- P23975
- Uniprot Name
- Sodium-dependent noradrenaline transporter
- Molecular Weight
- 69331.42 Da
References
- Gerson MC, Wagoner LE, McGuire N, Liggett SB: Activity of the uptake-1 norepinephrine transporter as measured by I-123 MIBG in heart failure patients with a loss-of-function polymorphism of the presynaptic alpha2C-adrenergic receptor. J Nucl Cardiol. 2003 Nov-Dec;10(6):583-9. [PubMed:14668769]
Drug created on May 15, 2010 18:19 / Updated on March 02, 2018 05:35